OptiBiotix sharpens profitability push as margins surge and costs fall
Life sciences group OptiBiotix Health has reported a year of improving financial performance and strategic refocus, as it sharpens its path towards commercial sustainability and profitability.
In an update for the year to 31 December 2025, the AIM-listed business posted a 30% rise in revenue to £1.13m, alongside an 82% jump in gross profit to £603,000.
Sales orders rose 33% to £1.34m, with £212,000 carried forward into 2026, while the company ended the year with a cash balance of £1.03m. It also retains strategic stakes in ... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...
